Erik J. Wiersma, Associate

Erik Wiersma is an Associate in Alba Biologics Group. Dr. Wiersma brings 20 years experience in project management and team building in the Research and Development field to the group. An experienced manager and scientist, Erik brings knowledge of the requirements to advance a therapeutic drug candidate from a project�s early bench research stage through the development path. Erik will overlay experience in preclinical sciences, quality assurance, GMP manufacturing as well as in Regulatory Affairs in the scientific advancement of a drug candidate development project.

Dr. Wiersma has a strong commitment to customer satisfaction and brings a proven track record of delivery in collaborative projects between industry, academia, and governmental institutions. Drawing from his broad scientific base and an extensive network, he offers:

  1. Assistance with identification, evaluation and selection of drug targets and lead drug candidates.
  2. Strategic pre-clinical development of drug candidates, including prioritization, trouble shooting and contingency plans.
  3. Assessment of market potential, competitive advantage and critical path to market.
  4. Drafting and reviewing scientific and regulatory documents including grant applications, study protocols, project reports, SOPs and regulatory submissions.
  5. Technical writing for business plans, budgets and patents.

As a research manager at Cangene Corporation, one of Canada�s largest biopharmaceutical companies, Dr. Wiersma was responsible for overseeing the therapeutic monoclonal antibody program. He also assisted in the development of recombinant vaccines and proteins, and was instrumental in obtaining external funding for several research and development projects from agencies including the NIH.

Selected Publications

(Additional to those common with other Alba Biologics Group members).

G. Soltes, H. Barker, K. Marmai, E.Pun, A. Yuen and E.J. Wiersma: A new helper phage and phagemid vector system improves viral display of antibody Fab fragments and avoids propagation of insert-less virions. J. Immunol. Methods, 2002, 2003; 274(1-2):233-44. Erratum in: J Immunol Methods. 2006;311(1-2):226.

L. Nickerson and E. J. Wiersma: Epitope mapping of four monoclonal antibodies specific for human RhD antigen. Immun.Lett.. 2001, 80:33-9.

E.J. Wiersma, D. Ronai, M. Berru, F. Tsui and M.J. Shulman. Role of the intronic elements in the endogenous immunoglobulin heavy chain locus. Either the matrix attachment regions or the core enhancer is sufficient to maintain expression. J Biol Chem. 1999, 274(8):4858-62.

E.J. Wiersma, D. Ronai, M. Berru, F. Tsui and M.J. Shulman. Role of the intronic elements in the endogenous immunoglobulin heavy chain locus. Either the matrix attachment regions or the core enhancer is sufficient to maintain expression. J Biol Chem. 1999, 274(8):4858-62.

E.J. Wiersma, C. Collins, S. Fazel and M.J. Shulman: Structural and functional analysis of J-chain-deficient IgM. J. Immunol. 1998, 160:5979-89.

E.J. Wiersma, F. Chen, R. Bazin, C. Collins, R.H. Painter, R. Lemieux and M.J. Shulman: Analysis of IgM structures involved in J chain incorporation. J. Immunol. 1997, 158:1719.

S. Fazel, E.J. Wiersma and M.J. Shulman: Interplay of J chain and Disulfide Bonding in Assembly of Polymeric IgM. Intern. Immunol. 1997, 9:1149-58.

E.J. Wiersma and M.J. Shulman: Assembly of IgM. Role of disulfide bonding and noncovalent interactions. J. Immunol., 1995, 154:5265-72.

A. Connor, E. Wiersma and M.J. Shulman: On the linkage between RNA processing and RNA translatability. J. Biol. Chem. 1994, 269:25178-25184.

E.J. Wiersma: Enhancement of the antibody response to protein antigens by specific IgG under different experimental condition. Scand. J. Immunol. 1992, 36:193-200.

E.J. Wiersma, T. Kinoshita and B. Heyman: Inhibition of immunological memory and T-independent humoral responses by monoclonal antibodies specific for murine complement receptors. Eur. J. Immunol. 1991, 21:2501-2506.

O. Israelsson, A. Peterssson, E. Bengten, E.J. Wiersma, J. Andersson, G. Gezelius and L. Pilstrom: Immunoglobulin concentration in Atlantic Cod, Gadus morhua L., serum and cross-reactivity between anti-cod antibodies and immunoglobulins from other species. J. Fish Biol. 1991, 39:265-278.

E.J. Wiersma, M. Nose and B. Heyman: Evidence of IgG-mediated enhancement of the antibody response in vivo without classical pathway complement activation. Eur. J. Immunol., 1990, 20:2585-2589.

B. Heyman, E.J. Wiersma and T. Kinoshita: In vivo inhibition of the humoral immune response by a complement receptor specific monoclonal antibody. J. Exp. Med. 1990, 172:665-668.

E.J. Wiersma, P.G. Coulie and B. Heyman: Dual immunoregulatory effects of monoclonal IgG antibodies: suppression and enhancement of the antibody response. Scand. J. Immunol., 1989, 29:439-448.

B. Heyman, E. Wiersma and M. Nose: Complement activation is not required for IgG-mediated suppression of the antibody response. Eur. J. Immunol. 1988, 18:1739-1743.

E.J. Wiersma, G. Froman, S. Johansson and T. Wadstrom: Carbohydrate specific binding of fibronectin to Vibrio cholerae cells. FEMS Microb. Lett. 1987, 44:365-369.

Copyright Alba Biologics Group.
About Services Our Team Publications Contact